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Introduction. The role of vinorelbine in speciﬁc soft tissue sarcoma subtypes is unclear. We present retrospective single institution
experience with single-agent vinorelbine in subjects with metastatic soft tissue malignancies. Methods. Fifty-eight patients were
treated with single agent intravenous vinorelbine between April 1997 and December 2004. Doxorubicin had been administered
previously to 53 subjects (91%), and the median number of lines of previous chemotherapy was 3 (range 0–7). Results. Patients
received a median 6 doses of vinorelbine (range 1–65). The overall response rate was 6% (3 patients: 1 angiosarcoma, 1 epithelioid
sarcoma, and 1 embryonal rhabdomyosarcoma). Fourteen patients (26%) experienced a best result of stable disease. Median time
to progression was 1.8 months (95% conﬁdence intervals 1.5–2.1 months, Kaplan-Meier estimate). Eight patients experienced
grade 3 or 4 toxicity, most commonly febrile neutropenia. Conclusion. Vinorelbine demonstrates limited activity in a heavily pre-
treated group of soft-tissue sarcoma patients. Prospective investigation may be considered for selected sarcoma subtypes.
Copyright © 2006 Sibyl E. Anderson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Soft-tissue sarcomas are a large group of rare and heteroge-
neous cancers from the extraskeletal connective tissues that
make up less than 1% of adult malignancies. Estimated inci-
dence of soft tissue sarcoma is 9530 new cases in the United
Statesin2006,anincidencerateofapproximately32permil-
lion [1]. Soft tissue sarcoma may originate in any part of the
bodyandmetastasizeprimarilytothelungsandalsotobone,
liver, and other organs depending on the subtype. The me-
dian survival for patients diagnosed with metastatic or re-
current unresectable sarcoma is usually less than 12 months
although a limited number of patients may have long term
survival as the result of optimal response to chemotherapy
[2]. Doxorubicin remains the most active drug in the treat-
mentofsofttissuesarcomawitharesponserateof10–25%in
previouslyuntreatedpatients[2].Otheractivedrugsorcom-
binations include ifosfamide [3], gemcitabine with or with-
out docetaxel [4, 5], and dacarbazine (DTIC) [6]. Treatment
options are therefore limited and responses are often of short
duration.
It is increasingly appreciated that each sarcoma subtype
has speciﬁc patterns of sensitivity to standard chemotherapy
agents. For example, leiomyosarcomas are often relatively re-
sistant to ifosfamide [2], and sensitive to dacarbazine [5],
compared to other sarcoma subtypes, and angiosarcomas
are relatively unique in their response to taxanes. Further-
more, clinical trials involving metastatic sarcomas allow only
limited lines of chemotherapy as an entry criterion, leav-
ing heavily treated subjects without well-examined options
among commercially available cytotoxic agents. There are re-
ports of responses of soft-tissue sarcoma patients to vinorel-
bine [7–9]. However, the role of vinorelbine in speciﬁc adult
soft-tissue sarcoma subtypes is unclear. We present here ret-
rospective single institution experience with vinorelbine in
selected soft-tissue sarcoma patients, many of whom were
heavily pretreated, in the hope of identifying subtypes of sar-
coma meriting prospective evaluation of this relatively non-
toxic agent.
METHODS
After Institutional Review Board (IRB) approval was ob-
tained, we reviewed our database of patients with recur-
rent or metastatic unresectable leiomyosarcoma treated by
Memorial Sloan-Kettering Cancer Center’s (MSKCC) Adult
Medical Oncology Service with vinorelbine between April,
1997 and December, 2004. Patients were treated with cycles
of vinorelbine chemotherapy consisting of 15 to 30mg/m2
weekly for 2 or 3 weeks, followed by 1 week rest. Patients’2 Sarcoma
charts were reviewed for age at time of vinorelbine ther-
apy, stage, performance status, prior chemotherapy treat-
ment, vinorelbine dose and schedule, best response to treat-
ment, and treatment delays or dose reductions due to toxi-
city. Responses were evaluated via CT scan or MRI, and as-
sessed according to response evaluation criteria in solid tu-
mors (RECIST) by radiologists at our institution. Overall
and progression-free survival curves were constructed and
Kaplan-Meier estimates were generated using SPSS version
12.0. We also performed a review of the literature pertaining
to vinorelbine in sarcomas.
RESULTS
Patient characteristics are indicated in Table 1. We identiﬁed
66 patients with soft-tissue sarcomas treated at Memorial
Hospital between April 1997 and December 2004. Five pa-
tients with GIST and three patients with deep ﬁbromatoses
(desmoid tumors) treated with vinorelbine were excluded,
leaving 58 patients, who form the group analyzed here. (No
patientswithGISTresponded;thebestresultfordesmoidtu-
mor was stable disease.) There were 26 men and 32 women
in the remaining group. The median age was 52 years (range
20–76 years). Forty-three patients (74%) had metastatic dis-
ease to lungs and 20 (34%) patients’ metastases involved
liver. Fifty of the tumors were termed high-grade; and seven
low-grade; for one a determination of grade could not be
made. Three patients had radiation-induced sarcomas. The
median Karnofsky performance status was 80% (range 60–
100%). The median number of previous chemotherapy reg-
imens was 3 (range 0–7), and median number of diﬀer-
ent chemotherapy drugs received was also 3 (range 0–14).
Fifty-three subjects (91%) of patients had received prior
doxorubicin-based chemotherapy.
Vinorelbinetherapyandclinical
andradiologicalresponses
The median starting dose of vinorelbine in this retrospec-
tive analysis was 25mg/m2 per dose (range 15–33mg/m2).
The median number of doses administered was 6 (range 1–
65). Eleven patients required a dose reduction; one patient
received two dose reductions over the course of her therapy.
Of the 58 patients examined, 3 patients (angiosarcoma,
epithelioid sarcoma, and embryonal rhabdomyosarcoma)
experienced a partial response, and received vinorelbine for
3.0, 27.4, and 4.8 months, respectively. No complete re-
sponses were observed. Two patients had minor responses
(angiosarcoma, MFH (malignant ﬁbrous histiocytoma, now
termed high-grade undiﬀerentiated pleomorphic sarcoma)).
Fourteen patients (26%) demonstrated stable disease as
best response, ﬁve patients experienced stable disease for
3 months or more and only one patient for more than 6
months. The Kaplan-Meier estimate for median time to pro-
gression for the entire cohort was 1.8 months (95% conﬁ-
dence intervals 1.5–2.1 months), see Figure 1. The Kaplan-
Meier median overall survival estimate was 6.4 months (95%
conﬁdence intervals 4.1–8.7 months), see Figure 2.
Table 1: Patient demographics.
Total number of subjects 58
Male 26 (45%)
Female 32 (55%)
Median age (range) 52 (20–76)
Subjects receiving prior doxorubicin 53 (91%)
High grade primary sarcoma 50 (88%)
Low grade primary sarcoma 7 (12%)
Unknown 1
Radiation-associated primary tumor 3 (5%)
Lung metastases present 43 (74%)
Liver metastases present 20 (54%)
Median prior lines of therapy (range) 3 (0–7)
Median prior total number of
agents administered (range)
￿ 3 (0–14)
Median KPS@(range) 80% (60%–100%)
Median number of doses of
vinorelbine administered (range) 6 (1–65)
Median starting dose (mg/m2) (range) 25 (15–33)
Histology:
Angiosarcoma 7
Cystosarcoma phylloides 1
Desmoplastic small round cell tumor 1
Endometrial stromal sarcoma 3
Epithelioid sarcoma 2
Ewing sarcoma/peripheral
neuroectodermal tumor 1
Fibromyxoid sarcoma 1
Fibrosarcoma 1
Leiomyosarcoma 20
Liposarcoma 4
Mesenchymal chondrosarcoma 1
MFH (malignant ﬁbrous histiocytoma) 8
Rhabdomyosarcoma, embryonal 1
Sarcoma, not otherwise speciﬁed 3
Synovial sarcoma 4
￿ Each drug only counted once, except ifosfamide, if given in high doses
￿10g/m2/cycle, which counts as a separate agent in this analysis.
@Karnofsky performance status.
TOXICITY
The primary toxicity was hematologic. The severity of tox-
icity did not appear to be related to dose or schedule. No
deaths were attributed to drug. No patients received prophy-
lactic ﬁlgrastim or pegﬁlgrastim. A total of 8 patients (14%)
experienced grade 3-4 toxicities that could be possibly, prob-
ably, or deﬁnitely related to vinorelbine administration. One
patient had ∼5cm 2 extravasation injury from vinorelbine,
given in a peripheral vein (grade 3 toxicity). Three patients
experienced febrile neutropenia (grade 3) after vinorelbine
chemotherapy. One patient was hospitalized for grade 4 mu-
cositis, one for pulmonary embolus (possibly related), oneSibyl E. Anderson et al 3
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Figure 1: Progression-free survival curve for patients receiving vi-
norelbine on this study (+ indicates censored patient).
for dehydration, nausea, and vomiting, and one for grade 3
obstipation requiring hospitalization.
DISCUSSION
Soft-tissue sarcomas are rare tumors for which salvage ther-
apies yield the unfortunate combination of short response
duration and relatively great toxicity. Doxorubicin has been
thestandardchemotherapeuticinterventionfor30years,and
remains the most eﬀective single agent [2]. The role and ac-
tivity of other salvage agents is becoming better deﬁned as
we learn which subtypes of sarcoma respond best to diﬀer-
ent cytotoxic agents, a reﬂection of more consistent pathol-
ogy review, better imaging, and a larger armamentarium of
chemotherapy agents to test. Vinorelbine is a well-tolerated
semisynthetic vinca alkaloid extracted from Vinca rosea, in-
hibiting microtubule assembly. Initial phase I and phase II
trials revealed neutropenia and neuropathy as its most com-
mon toxicities. In the present study, febrile neutropenia was
the most frequent signiﬁcant adverse event associated with
vinorelbine chemotherapy, and reﬂects not only the known
toxicities of vinorelbine but also the cumulative prior ther-
apy received by individual patients.
Pediatric sarcoma trials suggest a possible salvage role
for vinorelbine in selected adult sarcomas [7], as high-
lighted by the brief response of a patient with embryonal
rhabdomyosarcoma in this study. Thirty-three pediatric soft
tissue sarcoma patients were treated with weekly vinorelbine:
30mg/m2 in days 1 and 8 of 21-day schedule by the Pediatric
UnitoftheIstitutoNazionaleTumoriinMilan.Twenty-three
percent of patients had received 2 or more previous lines of
chemotherapy and 18 patients had metastasis to lung. Grade
3 or 4 neutropenia was observed in 27% and 36% of pa-
tients, respectively; occurring in 50% of patients who had
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Figure 2: Overall survival for patients receiving vinorelbine on this
study (+ indicates censored patient).
previously undergone high-dose chemotherapy with stem
cell rescue. Of 28 evaluable patients 28% achieved partial re-
sponse and 9 (32%) achieved stable disease. Impressive ac-
tivity was noted in rhabdomyosarcoma patients with 7 of
12 patients (58%) achieving partial or major response and
2 patients (8%) with stable disease. One of 5 osteosarco-
mas (20%) achieved PR and 1 of 7 (14%) Ewing sarcomas
achieved PR. Median duration of partial response was 10
months and stable disease 3.5 months. The remaining 10 pa-
tients progressed on therapy.
Single-agent vinorelbine also demonstrates activity in
AIDS-associated Kaposi sarcoma [8]. Of 35 assessable adult
patients treated by the Italian Cooperative Group on AIDS
and Tumors with vinorelbine 30mg/m2 every 2 weeks, 34%
achieved a partial response and 9% acheived a complete re-
sponse for a median duration of 176 days. Of note, all pa-
tientsreceivedpriorchemotherapy.Nonhematologictoxicity
was uncommon. The most common toxicity observed was
neutropenia: grade 4 (30%) and grade 3 (21%) with the ma-
jority of patients requiring ﬁlgrastim to support their neu-
trophil counts. Thirty-six severely immune-compromised
patients were treated with no toxic-related deaths reported.
Fidias et al performed a phase II trial of weekly vinorel-
bine at 30mg/m2 in 37 adult sarcoma patients who failed
doxorubicin-based therapy [9]. Activity was observed in an-
giosarcoma and leiomyosarcoma patients. Of 35 evaluable
patients 1 demonstrated a complete response and 6 showed
partial responses. Three patients demonstrated stable dis-
ease. Of 4 patients with angiosarcoma, one demonstrated
complete response, and 2 a mixed response.
Given the relative chemoresistance of soft-tissue sarco-
mas, and patterns of response seen for a variety of sarcomas,
stable disease and time to progression may indicate a sig-
niﬁcant response and therefore may be a more appropriate
therapeutic endpoint than response per se. Van Glabbeke4 Sarcoma
and colleagues investigated what a reasonable estimate for
progression-free survival at 3 and 6 months are for ac-
tive and inactive agents by examining the results from
prospective clinical trials conducted by the EORTC [10]. The
progression-free rates were 39% and 14% at 3 months and 6
months, respectively, for agents that were active, in compari-
son to 21% and 8% for inactive agents. The progression free
rateforvinorelbineinthiscohortofpatientswasonly18%at
3monthsand2%at6months,indicativeofaninactiveagent.
However, this may not be a fair comparison, since vinorel-
bine in this analysis was given in 4th line (median) in com-
parison to 1st or 2nd line in the EORTC database analysis.
There is an increasing body of evidence supporting the
variable response of soft-tissue sarcoma subtypes. Initial sal-
vage combination trials of vinorelbine suggest such com-
binations have activity in selected adult and pediatric soft-
tissue sarcomas. The activity of vinorelbine as a single agent
isminorcomparedtothehigherresponsesrates,timetopro-
gression, and overall survival seen for gemcitabine and do-
c e t a x e li ns u b j e c t sw i t hl e i o m y o s a r c o m a[ 5], MFH [11–13],
and pleomorphic liposarcoma [13] ,a n do fE T - 7 4 3( tra bect e -
din) for patients with myxoid-round cell liposarcoma [14].
Nonetheless, this small retrospective investigation suggests
vinorelbinepotentiallyhasantitumoractivityinspeciﬁcsoft-
tissue sarcomas and is relatively well tolerated in heavily
pretreated patients. A further prospective analysis in less
heavily treated patients with rhabdomyosarcoma, angiosar-
coma, and epithelioid sarcoma appears warranted, based
on the hints of activity seen in this highly selected popu-
lation of patients well enough to tolerate multiple lines of
therapy.
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